Arcturus Therapeutics Holdings (ARCT) Short term Debt (2020 - 2022)

Arcturus Therapeutics Holdings has reported Short term Debt for 3 years, with the latest figure at $60.7 million in Q4 2022.

• For the quarter ending Q4 2022, Short term Debt rose 169.89% year-over-year to $60.7 million; the trailing twelve-month figure through Dec 2022 stood at $60.7 million (up 169.89% YoY), and the FY2022 full-year result was $60.7 million, up 169.89% from the prior year.
• Short term Debt for Q4 2022 stood at $60.7 million, up from $27.7 million in the prior quarter.
• The five-year high for Short term Debt was $60.7 million in Q4 2022, with the low at $1.2 million in Q4 2020.
• Historically, Short term Debt has averaged $21.1 million across 3 years, with a median of $22.5 million in 2021.
• Annual changes were most pronounced in 2021 — Short term Debt jumped 1697.92% — and 2022, when it surged 49.89%.
• Arcturus Therapeutics Holdings' Short term Debt stood at $1.2 million in 2020, then jumped by 1697.92% to $22.5 million in 2021, then jumped by 169.89% to $60.7 million in 2022.
• The last three Short term Debt figures came in at $60.7 million (Q4 2022), $27.7 million (Q3 2022), and $27.0 million (Q2 2022), per Business Quant data.